Trial
NCT02439970
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus Disease
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Jazz Pharmaceuticals
Collaborators
—
Condition
Cytomegalovirus Disease
Intervention
Brincidofovir
Why stopped
Study was terminated early due to results from another CMX001 study
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-07-16